Airway Stent Lung Stent Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Airway and lung stents are tubular implants deployed in the central airways to relieve obstruction caused by tumors, strictures, or external compression, and they are typically placed via bronchoscopic or rigid bronchoscopy procedures. The global market is currently estimated at roughly $15.39 billion in 2025 and is projected to grow at 3.7% annually. Tracheal, bronchial, tracheobronchial, and laryngeal stents constitute the principal product categories, with self-expandable metallic and silicone-based designs representing the leading technology platforms.

• •2025 global market value estimated at ~$15.39 billion with 3.7% CAGR through the forecast window
• •Major indications include malignant airway obstruction, post-traumatic stenosis, and benign strictures
• •Deployment is overwhelmingly performed by interventional pulmonologists and thoracic surgeons in hospital settings

Rising global incidence of lung cancer and other thoracic malignancies is increasing demand for palliative airway stenting, while aging populations in developed and emerging markets are expanding the eligible patient pool. Parallel improvements in bronchoscopic imaging, navigation platforms, and stent materials are making procedures safer and more broadly adopted. In addition, growing reimbursement coverage for interventional pulmonology in North America, Europe, and parts of Asia is accelerating hospital uptake of these devices.

• •Increasing lung cancer and COPD prevalence is expanding the addressable patient population
• •Advances in drug-eluting, bioresorbable, and hybrid stent designs are improving clinical outcomes
• •Wider reimbursement and training in interventional pulmonology are supporting procedural volume growth

By product type, the market is segmented into self-expandable metallic stents, balloon-expandable stents, and silicone stents, with self-expandable designs historically dominating revenue share. By application, tracheal and bronchial stents lead demand, followed by tracheobronchial and laryngeal variants. North America accounts for the largest regional share due to high procedure volumes and advanced healthcare infrastructure, while Asia-Pacific is the fastest-growing region on the back of expanding cancer care capacity in China, India, and Southeast Asia.

• •Self-expandable metallic stents hold the largest product segment share, with silicone and balloon-expandable alternatives serving niche indications
• •Tracheal and bronchial stents together represent the bulk of unit and revenue demand
• •North America leads current revenue, while Asia-Pacific is projected to register the highest growth rate through 2030

What are the recent trends and outlook?

The next phase of market expansion is expected to be shaped by the transition from purely mechanical stents toward drug-eluting and bioresorbable platforms designed to reduce granulation tissue, migration, and re-intervention rates. Adoption of robotic and electromagnetic bronchoscopy is improving placement precision, supporting use in earlier-stage disease and more complex anatomy. Over the forecast horizon, demand is likely to remain resilient as lung cancer screening programs increase detection of central airway tumors and as emerging markets scale up advanced pulmonology services.

• •Drug-eluting and bioresorbable stent designs are a key pipeline focus area for major manufacturers
• •Integration with robotic and electromagnetic bronchoscopy platforms is improving placement accuracy
• •Long-term demand is supported by expanded lung cancer screening and rising pulmonology capacity in emerging markets